DOCSLIB.ORG

Curriculum Vitae

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curriculum Vitae C. Vitae Jordi Monés 1 CURRICULUM VITAE, July, 2018 Jordi M. Monés PERSONAL DATA. 1. EDUCATION / QUALIFICATIONS 2. PRESENT PROFESSIONAL POSITIONS 3. PAST POSITIONS 4. INTERNATIONAL AWARDS 5. ADVISORY BOARDS and RESEARCH COMMITTEES 6. COLLABORATIVE EUROPEAN RESEARCH PROJECTS 7. BASIC RESEARCH PROJECTS 8. CLINICAL TRIALS 9. SCIENTIFIC PUBLICATIONS 10. SCIENTIFIC PRESENTATIONS 11. GRANTS 12. TEACHING ACTIVITIES and INVITED LECTURES 13. COLLABORATION IN JOURNALS EDITION and REVIEWER 14. THESIS 15. SCIENTIFIC SOCIETIES MEMBERSHIP 16. LANGUAGES C. Vitae Jordi Monés 2 PERSONAL DATA: Name: Jordi Manel Monés i Carilla (Jordi M. Monés) Address: Institut de la Màcula Centro Médico Teknon Àrea Vilana. Building 90 Vilana 12, 08022 Barcelona SPAIN Telephone +34 93 5950155 Fax +34 93 5950345 E- mail: [email protected] Web: www.institutmacula.com Date of Birth: Barcelona, June 25, 1961. 1. EDUCATION / QUALIFICATIONS: 1.1. 09/1979 - 06/1985: LICENCIATE IN MEDICINE AND SURGERY. Qualification: Excellent. University of Barcelona. Barcelona, SPAIN. 1.2. 01/1986: SPANISH NATIONAL BOARD EXAMINATION for a Residency Position M.I.R.1985/6: National classification number: 84. 1.3. 1/86 - 12/1989: RESIDENCY IN OPHTHALMOLOGY, (Opthalmologist M.I.R.) Barraquer Institute, Barcelona, SPAIN. 1.4. 1/1990 - 06/1991: RESEARCH FELLOWSHIP IN OPHTHALMOLOGY (RETINA SERVICE). The Massachusetts Eye and Ear Infirmary, Harvard University. Boston, U.S.A. C. Vitae Jordi Monés 3 1.5. 07/1991 - 07/1992: SURGICAL VITREORETINAL FELLOWSHIP. CLINICAL AND SURGICAL RETINA FELLOWSHIP. Retina Department, Hospital San José. Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM). Monterrey, MEXICO. 1.6. 06/2010 - 06/2012: DOCTORAL THESIS, Ph.D. Degree. DOCTOR IN MEDICINE AND SURGERY, Qualification: Cum Laude. University of Barcelona, SPAIN. 2. PRESENT PROFESSIONAL POSITIONS: 2.1. CURRENT: 2.1.1. M.D., Ph.D., Opthalmologist, Macula and Vitreorretinal Specialist and Researcher. 2.1.1.1. Founder and Director of the Institut de la Màcula Centro Médico Teknon, Àrea Vilana, Building 90, Vilana 12, 08022 Barcelona, since 2007. 2.1.1.2. Director, principal investigator and one of the founders of the Barcelona Macula Foundation: Research for Vision, since 2011. 2.1.1.3. Elected Coordinator of the Specialty of Ophthalmology at the Centro Médico Teknon, since 2010 2.1.1.4. Institut de la Màcula i de la Retina Acredited site of the network of excellence in research, European Vision Institute www.europeanvisioninstitute.org/ 2.1.1.5. Member of the Steering Committee at the International Multicenter Clinical Trials Proxima A and Proxima B on Geographic Atrophy. Roche, Basel, Switzerland 2.1.1.6. Member of the Steering Committee at the International Multicenter Clinical Trials Brighter and Crystal. Novartis. C. Vitae Jordi Monés 4 2.1.2. Scientific Advisory Boards 2.1.2.1. Member of the Scientific Advisory Board of AMD international Alliance 2.1.2.2. Member of the Region Europe Ophthalmics Network (REONET) advisory board, Novartis 2.1.2.3. Member of the European Advisory Board on Retinal Vein Occlusion, ERAB, Allergan Inc 2.1.2.4. Scientific Advisor of Opththech Inc, New York USA 2.1.2.5. Scientific Advisor of Notalvision Inc, Tel Aviv, Israel 2.1.2.6. Member of the International Advisory Board for Eylea® (VEGF- Trap eye) Bayer Schering Pharma 2.1.2.7. Clinical Advisor of CellCure NeuroSciences Ltd. 2.1.3. Other positions: 2.1.3.1. Member of the Board of Directors of Futbol Club Barcelona and Responsible of the Medical Department and Performance from 2003- 2005, and 2010-2015. 2.1.3.2. Member of the Board of Directors, Comissioner FC Barcelona Universitas and Responsible for the Sport Sciences Department, 2015-2017. 2.1.3.3. Member of the National Council of Centre for Integration of Medicine and Innovative Technologies in Catalonia (CIMTI). November, 2017 3. PAST POSITIONS: Consultant as Vitreoretinal Specialist Ophthalmologist in: 3.1. Institut de Microcirurgía Ocular de Barcelona. (April 1993 -December 2006) C. Vitae Jordi Monés 5 3.2. Hospital de la Creu Roja de Barcelona (1995 - Nov 2004), Consultant Ophthalmology Service. Vitreoretinal Surgery. 3.3. Associate Profesor Universitat Autònoma de Barcelona in: (2003 - 2006) Cátedra (Professorship) Institut de Microcirurgia Ocular de Barcelona Universitat Autónoma de Barcelona 3.4. Member of the Board of Directors (Junta Directiva) of FUTBOL CLUB BARCELONA. Responsible of the Medical and Sport Medicine Department of Futbol Club Barcelona. June 03 - June 05 3.5. Elected Coordinator of the Specialty of Ophthalmology at the Centro Médico Teknon. Feb 10 - Feb 12 Main Fields of professional interests: His research particular fields of interest are macular diseases, choroidal neovascularization, macular degeneration, antiangiogenic therapy, anti PDGF therapy, geographic atrophy, retinal degeneration, retinal transplant, stems cells, gene therapy, macular edema, and vitreoretinal and macular surgery. 4. INTERNATIONAL AWARDS: 4.1. Co-Winner of the INTERNATIONAL AWARD OF EXPERIMENTAL SURGERY Banc de Sabadell, Acadèmia de Medecina de Barcelona, i Col.legi Oficial de Metges de Barcelona, with the Research Project: "Photodynamic Therapy of the Experimental Posterior Malignant Melanoma" (Massachusetts Eye and Ear Infirmary, Harvard University, Boston, USA. Director of the Project: Evangelos Gragoudas MD). Barcelona, June 18, 1991. 4.2. Premi a la Recerca Científica en DMAE. Associació Discapacitat Visual de Catalunya. 30 Novembre 2011 4.3. Academy's Achievement Award 2015. American Academy of Ophthalmology. C. Vitae Jordi Monés 6 5. ADVISORY BOARDS AND RESEARCH COMMITTEES 5.1. 1999: Rotating Member of Study Advisory Group of the “Randomized, Placebo-Controlled, Masked, Multicenter, Phase III b Study of the Treatment of the Subfoveal Neovascularization Secondary to Age-Related Macular Degeneration and pathologic myopia Using Photodynamic Therapy with Liposomal BPD-MA Verteporfin” Institut de Microcirurgia Ocular de Barcelona. 5.2. 2000: Rotating Member of Study Advisory Group of the “Photodynamic Therapy using Verteporfin Study VER, VIO and VIM”. Institut de Microcirurgia Ocular de Barcelona. 5.3. 2003: Member of the International Consultant Committee for Research in AMD, Novartis International, Basel, Switzerland. 5.4. 2003 – 2005: Member of the International Council for Research of Retinal Diseases of Eyetech Co. New York, USA 5.5. 2003 – Ongoing: Scientific Consultant of Notalvision, Co. Tel-Aviv, Israel. 5.6. 2003 – 2006: Member of the Macula Society Research Committee 5.7. 2008 Allergan advisory board. Annual Meeting Association for Research in vision and ophthalmology, Fort Lauderdale, USA. May 1-5 2008 5.8. 2008 Advisory Board Meeting Ophthotech for new treatments for exudative and Dry AMD London, 30 and 31 October, London 5.9. 2008 Advisory board Allergan for Posurdex device for the treatment of macular edema secondary to retinal vein occlusion and diabetic macular edema. American Academy of Ophthalmology, November 9. Atlanta, USA 5.10. 2008 Advisory Board for Preferential Hyperacuity Perimeter. Notalvision, Israel. 5.11. (from 2008 please see in section 13.2) C. Vitae Jordi Monés 7 6. COLLABORATIVE EUROPEAN RESEARCH PROJECTS 6.1. 2013- 2016: LITE: Laser imaging Techniques for the anterior and posterior eye. Institut de Ciències Fotòniques; Istituto Nazionale di Ottica; Istituto di Fisica Applicata Nello Carrara, Construzione Strumenti Oftalmici and Institut de la Màcula i de la Retina (Principal investigator in Catalonia Site). ERANET Biophotonics. European Comission Financed 6.2. 2015-2016: PRO4VIP: Innovative PROcurement for Visually Impaired People. European Pre-Commercial Public Procurement (PCP) and Innovative Public Procurement (IPP) project that forms part of the European Vision 2020 strategy. Coordinated by AQuAS (Generalitat de Catalunya), it enjoys the participation of the Barcelona Macula Foundation, together with 12 other institutions from England, the rest of Spain, Denmark, France and Italy. Financed by H2020. 6.3. 2015-Ongoing: EYE RISK. Exploring the combined role of genetic and non- genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways (EYE-RISK). Topic PHC-01-2014. Horizon 2020. Coordinated by Eberhard Karls Universitaet Tuebingen (EKUT), it enjoys the participation of the Barcelona Macula Foundation, together with 10 other institutions. Financed by H2020. 6.4. 2016- On going. ADVANCE.CAT. Accelerating Development ON Advanced Teraphies in Catalonia. RIS3CAT communities. The research and innovation strategy of Catalonia. Generalitat de Catalunya. Financed by FEDER source. 7. BASIC RESEARCH PROJECTS 7.1. 2012 - 2016: Principal Investigator, The geographic atrophy in pig study (the GAP study): A phase I escalating dose of subretinal sodium iodate: a toxic- induced animal model of geographic atrophy of RPE and photoreceptors. Institut de la Màcula i de la Retina, Barcelona Macula Foundation C. Vitae Jordi Monés 8 7.2. 2016- On going: Principal Investigator. Translational Research in regenerative stem cell therapies for retinal degenrative diseases from the swine animal model of retinal atrophy to clinical trials in human patients with age-related macular degeneration, retinitis pigmentosa and Stargardt’s disease. Barcelona Macula Foundation. Barcelona Macula Foundation (BMF), Centre de Medicina Regenerativa de Barcelona (CMRB), Banc de Sang i Teixitis (BSiT) and Fundación Leitat. 7. CLINICAL TRIALS 7.1. 1989: Principal Investigator
Load more

Recommended publications
  • AMD Update 1 Hr Ho
    Introduction • AMD is the leading cause of vision loss in Americans over the age of 60 • Advanced AMD is the leading cause of vision loss and irreversible blindness worldwide in those over the age of 50 • As many as 11 million Americans have some level of AMD UPDATE ON AMD 2021 – Expected to increase to nearly 22 million by 2050 • More than glaucoma (2.2 million) and DR (7.7 million) Steven Ferrucci, OD, FAAO COMBINED Chief, Optometry Sepulveda VA Professor, SCCO/MBKU 1 2 Introduction Dry AMD • Exciting time to be interested in AMD • Currently mainstay treatment for Dry AMD revolves around prevention of progression through vitamins, nutrition and lifestyle • Many new treatments now available for AMD changes – Years ago, we had nothing at all to offer patients with AMD – Rheophoresis, Laser, Anecortave Acetate did not prove effective – Smoking #1 modifiable risk factor for getting AMD as well as its • Current Treatments progression! • Potential Treatments • One study showed 90% of pts with AMD were not advised to quit smoking • Early detection of conversion from dry to wet may result in better • New Diagnostic Equipment treatment for patients 3 4 AREDS AREDS 2 • First large scale study looking at nutrition and ocular health • AREDS 2: Enrollment ended June 2008 with ≈4200 patients followed • 3640 pts followed on average for 6.3 years for six years – Effect of lutein, zeaxanthin and omega 3 on AMD – Results released October 2001 – Effect of eliminating beta carotene on AMD • Results showed that 25% risk reduction to developing advanced
    [Show full text]
  • Ranibizumab, Lucentis®)
    Clinical Development RFB002 (Ranibizumab, Lucentis®) Clinical Trial Protocol CRFB002DDE26 / NCT02366468 A 12-months, randomized, VA-assessor blinded, multicenter, controlled phase IV trial to investigate non- inferiority of two treatment algorithms (discretion of the investigator vs. pro re nata) of 0.5 mg ranibizumab in patients with visual impairment due to diabetic macula edema Authors: Document type: Clinical Trial Protocol EUDRACT number: 2014-002854-37 Version number: v01 (incl. Amendment 01) Development phase: IV Release date: 18-04-2016 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis NOVDD Template Version 03-Feb-2012 Novartis Confidential Page 2 Clinical Trial Protocol (Version No. 01) Protocol No. CRFB002DDE26 Table of contents Table of contents ................................................................................................................. 2 List of tables ........................................................................................................................ 5 List of figures ...................................................................................................................... 5 List of abbreviations ............................................................................................................ 6 Glossary of terms ................................................................................................................. 8 Summary of protocol amendments .....................................................................................
    [Show full text]
  • Age-Related Macular Degeneration (Amd)
    EUnetHTA Joint Action 3 WP4 Relative effectiveness assessment of pharmaceutical technologies BROLUCIZUMAB FOR THE TREATMENT OF ADULTS WITH NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (AMD) Project ID: PTJA09 Version 1.0, 12/03/2020 Dec2015 ©EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 PTJA09 - Brolucizumab for patients with neovascular (wet) AMD DOCUMENT HISTORY AND CONTRIBUTORS Version Date Description V0.1 28/01/2020 First draft V0.2 24/2/2020 Input from dedicated reviewers has been processed V0.3 10/03/2020 Input from medical editor and manufacturer(s) has been processed V1.0 12/03/2020 Final assessment report Disclaimer This Joint Assessment is part of the project / joint action ‘724130 / EUnetHTA JA3’ which has received funding from the European Union’s Health Programme (2014-2020). The content of this Assessment Report represents a consolidated view based on the consensus within the Authoring Team; it cannot be considered to reflect the views of the European Network for Health Technology Assessment (EUnetHTA), EUnetHTA’s participating institutions, the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains. Assessment team Author(s) Finnish Medicines Agency (Fimea), Finland Co-Author(s) Spanish Agency of Medicine and Sanitary Products (AEMPS), Spain Andalusian Unit for Health Technology Assessment (AETSA), Spain Dedicated French National Authority for Health (HAS), France Reviewer(s) Agency for Health Technology Assessment and Tariff System (AOTMiT), Poland Regione Emilia-Romagna (RER), Italy Association of Austrian Social Insurance Institutions (DVSV), Austria Observer HTA Department/EC Ukraine, Ukraine March 2020 EUnetHTA Joint Action 3 WP4 1 PTJA09 - Brolucizumab for patients with neovascular (wet) AMD Further contributors External experts Prof.
    [Show full text]
  • Pharmacologic Treatment of Wet Type Age-Related Macular Degeneration; Current and Evolving Therapies
    H. Shams Najafabadi, N. Daftarian, H. Ahmadieh, et al. Review Article Pharmacologic Treatment of Wet Type Age-related Macular Degeneration; Current and Evolving Therapies Hoda Shams Najafabadi1, Narsis Daftarian2, Hamid Ahmadieh3, Zahra-Soheila SoheiliƔ1 Abstract $JHUHODWHGPDFXODUGHJHQHUDWLRQDVWKHPDMRUFDXVHRIEOLQGQHVVLQWKHHOGHUO\SRSXODWLRQKDVUHPDLQHGDWWKHHSLFHQWHURIFOLQLFDO UHVHDUFKLQRSKWKDOPRORJ\7KLVUHWLQDOGLVRUGHULVFKDUDFWHUL]HGE\WKHSKRWRUHFHSWRUDQGUHWLQDOSLJPHQWHSLWKHOLDOFHOOVORVVRFFXUULQJ ZLWKLQWKHPDFXOD 7KHGLVHDVHUHSUHVHQWVDVSHFWUXPRIFOLQLFDOPDQLIHVWDWLRQV,WLVDPXOWLIDFWRULDOGLVHDVHUHVXOWLQJIURPDFRPELQDWLRQRI JHQHWLFSUHGLVSRVLWLRQVDQGHQYLURQPHQWDOULVNIDFWRUV$0'LVFODVVL¿HGLQWRWZRGLIIHUHQWW\SHVGU\DQGZHW:HW$0'LVLQFORVHUHODWLRQ ZLWKDQJLRJHQHVLVDQGLQÀDPPDWRU\SURFHVVHV$YDULHW\RIDQWLDQJLRJHQHVLVDQGDQWLLQÀDPPDWRU\GUXJVKDYHEHHQSURSRVHGIRUWKH WUHDWPHQWRIWKHGLVHDVH7KHSXUSRVHRIWKLVSDSHULVWREULHÀ\UHYLHZWKHSKDUPDFRORJLFDOWKHUDSLHVRIWKHZHWIRUPRI$0'DQGIRFXVRQ QHZGUXJVWKDWDUHFXUUHQWO\LQGLIIHUHQWVWDJHVRIUHVHDUFKDQGGHYHORSPHQW Keywords: $JHUHODWHGPDFXODUGHJHQHUDWLRQDQJLRJHQHVLVDQWLDQJLRJHQHVLVGUXJVDQWLLQÀDPPDWRU\GUXJVLQÀDPPDWLRQ Cite this article as: Shams Najafabadi H, Daftarian N, Ahmadieh H, Soheili ZS, et al. Pharmacologic Treatment of Wet Type Age-related Macular Degeneration; Current and Evolving Therapies. Arch Iran Med. 2017; 20(8): 525 – 537. Introduction Anatomy of the eye The human eye has three main layers. The outermost layer of JHUHODWHG PDFXODU GHJHQHUDWLRQ ZDV ¿UVW LQWURGXFHG LQ the eye is called the sclera, which is composed of connective
    [Show full text]
  • Early Response of Retinal Angiomatous Proliferation Treated With
    Eye (2009) 23, 530–535 & 2009 Macmillan Publishers Limited All rights reserved 0950-222X/09 $32.00 www.nature.com/eye CLINICAL STUDY Early response of S Mahmood, N Kumar, PM Lenfestey, S Murjaneh, H Heimann and SP Harding retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review Abstract stabilizing effect on this normally progressive disease. Aims To evaluate the early functional and Eye (2009) 23, 530–535; doi:10.1038/eye.2008.101; anatomical responses to intravitreal published online 18 April 2008 pegaptanib in patients with retinal angiomatous proliferation (RAP). Keywords: pegaptanib; intravitreal; retinal Methods Retrospective review of consecutive angiomatous proliferation; macugen patients newly diagnosed with RAP treated with intravitreal pegaptanib (0.3 mg). Examination at baseline and 12 weekly intervals included refraction protocol best Introduction corrected visual acuity (BCVA), fluorescein angiography (FA), and optical coherence Retinal angiomatous proliferation (RAP) is a tomography (OCT). At intervening 6 weekly form of neovascular age-related macular visits a reduced protocol assessment included degeneration (AMD) in which intraretinal BCVA and OCT. neovascularisation (stage I) progresses to Results A total of 16 eyes of 16 patients subretinal neovascularisation with or without (12 female, mean age 76.0 years) with RAP serous pigment epithelial detachment (PED) at baseline (15 stage 3, one stage 2) were (stage II), followed by choroidal treated. One patient had poor response, neovascularisation (CNV) (stage III).1,2 It is losing 20 ETDRS letters after one injection estimated to comprise 10–15% of all newly and was switched to photodynamic therapy St Paul’s Eye Unit, Royal diagnosed neovascular AMD and 30% of occult 3 Liverpool University combined with intravitreal triamcinolone.
    [Show full text]
  • Age Related Macular Degeneration (AMD) Is a Common Condition Seen in General Practice
    CLINICAL PRACTICE Age related macular Update degeneration New developments in treatment Timothy C Smith BACKGROUND MBBS, is a pre-clinical Fellow, Age related macular degeneration (AMD) is a common condition seen in general practice. Over the past few years, new City Eye Centre, Brisbane, understanding of the condition has seen the rapid development of increasingly effective treatments. Queensland. [email protected]. OBJECTIVE edu.au This article discusses the pathogenesis of AMD and how this relates to the most up to date treatments for the disease. It Lawrence Lee aims to provide general practitioners with timely information regarding these significant advances, which may assist in the MBBS, FRANZCO, FRACS, management of patients with AMD. is Associate Professor, Department of Ophthalmology, DISCUSSION University of Queensland. Increasingly, AMD sufferers independently source information about the latest treatments. Consequently GPs are likely to hear more questions from their patients regarding treatment options. Antivascular endothelial growth factor drugs show exciting potential for an often debilitating condition. However, early referral and treatment is vital to successful outcomes and GPs can play an essential role in this process. As well, they can serve to provide ongoing information and counselling to their patients with AMD. Age related macular degeneration (AMD) is a disorder choroidal neovascular membrane (CNVM) (Figure 2). The that usually presents in patients aged over 55 years. The new growth of these aberrant blood vessels into the pathology involves the destruction and deterioration of retina helps to explain the rapid visual loss experienced the dense neurosensory layer specific to the macula.1 by patients. A characteristic of the neovascularisation The disorder is usually categorised into: process is the tendency for abnormal blood vessels to • exudative or ‘wet’ form, and leak exudates and occasionally to haemorrhage.
    [Show full text]
  • WO 2018/217651 Al 29 November 2018 (29.11.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/217651 Al 29 November 2018 (29.11.2018) W !P O PCT (51) International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, C07D 471/04 (2006.01) A61P 35/00 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, A61K 31/519 (2006.01) C07D 475/00 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, (21) International Application Number: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. PCT/US2018/033714 (84) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of regional protection available): ARIPO (BW, GH, 2 1 May 2018 (21 .05.2018) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (25) Filing Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (26) Publication Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (30) Priority Data: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 62/509,629 22 May 2017 (22.05.2017) US TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2018-022031 on 28 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay- per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 24, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-022031 on 28 May 2019. Downloaded from Anti–Vascular Endothelial Growth Factor Treatment for Retinal Conditions: A Systematic Review and Meta-analysis Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-022031 review only Article Type: Research Date Submitted by the Author: 29-Jan-2018 Complete List of Authors: Pham, Ba; Li Ka Shing Knowledge Institute, St.
    [Show full text]
  • Eylea, INN-Aflibercept
    London, 22 January 2015 EMA/CHMP/13670/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Eylea International non-proprietary name: AFLIBERCEPT Procedure No. EMEA/H/C/002392/II/0013 Note Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 5 1.1. Type II variation .................................................................................................. 5 1.2. Steps taken for the assessment of the product ......................................................... 6 2. Scientific discussion ................................................................................ 6 2.1. Introduction......................................................................................................... 6 2.2. Non-clinical aspects .............................................................................................. 7 2.2.1. Ecotoxicity/environmental risk assessment ........................................................... 7 2.3. Clinical aspects ...................................................................................................
    [Show full text]
  • Ezetimibe for the Treatment of Hypercholesterolemia
    Pegaptanib & Ranibizumab for the Treatment of Age-related Macular Degeneration Comments on Appraisal Consultation Document (ACD) H:\Appraisals\0 - Eye\Macular degeneration (age-related) - anecortave acetate, pegaptanib & ranibizumab (H)\ACD2\Evaluation Report\comments on ACD\Commentators\DHSSPSNI comment (stripped).doc Name of Commentator: xxxxxxxxxxxxxxxxxxxxxxxx on behalf of DHSSPSNI Conflict of Interest Declaration Please state if, at any time, you have had any involvement with the health care industry or manufacturers (as listed in the list of stakeholders) in relation to the technology being appraised and have personally received payment or material benefit from that work. If so, please provide details including the date of your last involvement. Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Comments on Pegaptanib & Ranibizumab for the Treatment of Age-related Macular Degeneration I don’t have any substantive comments on the guidance issued on pegaptanib. I agree that the outcomes in the VISION trials show effectiveness in preventing moderate and severe vision loss but were not substantive enough for cost effectiveness. I have a number of comments on the guidance on ranibizumab. Restriction to predominantly classic
    [Show full text]
  • Dr. Steinmetz CV Updated 120318
    Robert Steinmetz, MD 2439 Care Dr., Tallahassee, FL 32308 Phone: 850.942.6700 Fax: 850.942.5735 E-Mail: [email protected] EDUCATION B.A. Magna Cum Laude, Luther College, Decorah, Iowa M.D. University of Iowa College of Medicine, Iowa City, Iowa POSTGRADUATE TRAINING • The Gundersen Medical Foundation, LaCrosse Lutheran Hospital, LaCrosse, Wisconsin Rotating Internship 1982 - 1983 • The University of Utah, Salt Lake City, Utah Ocular Pathology Fellowship with David J. Apple, M.D. 07/1983 - 10/1983 • Pacific Presbyterian Medical Center, San Francisco, California Residency in Ophthalmology 11/1983 - 10/1986 • The Jules Stein Eye Institute, UCLA, Los Angeles, California Fellowship in Vitreous and Retinal Diseases and Surgery 07/1987 – 06/1989 • Moorfields Eye Hospital, London, England Medical Retina Fellow to Alan C. Bird, M.D., FRCS 07/1989- 02/1991 TEACHING APPOINTMENTS • University of Essen Eye Hospital, Essen, Germany Oberarzt, (senior staff member) Director: Prof. Dr. A. Wessing 05/1991 - 02/1992 • University of Bonn Eye Hospital, Bonn, Germany Oberarzt, Director: Prof. Dr. M. Spitznas 03/1992 - 12/1992 • Florida State University, School of Medicine Clerkship Faculty 11/2003 - present EMPLOYMENT POST TRAINING • Southern Vitreoretinal Associates, PPL 1993 - present CERTIFICATION AND LICENSURE • American Board of Ophthalmology 1990 Licensed Physician in the states of Florida, Georgia, and Alabama HOSPITAL AFFILIATIONS • Tallahassee Memorial Hospital, Tallahassee, FL • Phoebe Putney Memorial Hospital, Albany, GA Robert Steinmetz, MD Page 2 HONORARY SOCIETIES • American Academy of Ophthalmology (fellow) 1990 • American Society of Retinal Surgeons (Vitreous Society) 1997 • The Retina Society 2005 ASSOCIATIONS • American Medical Association 1993 • Florida Society of Ophthalmology 1998 AWARDS • Abe Meyer Fellowship 1987 - 1989 PUBLICATIONS Peer-reviewed Journal Articles: Apple DJ, Craythorn JM, Reidy JJ, Steinmetz RL, Brady SE, and Bohart WA.
    [Show full text]
  • The Evolving Role of Vascular Endothelial Growth Factor Inhibitors
    Eye (2008) 22, 761–767 & 2008 Nature Publishing Group All rights reserved 0950-222X/08 $30.00 www.nature.com/eye The evolving role of H Dadgostar and N Waheed REVIEW vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration Abstract Keywords: VEGF; age related macular degeneration; Intravitreal injection Age-related macular degeneration (AMD) is the leading cause of blindness among the ageing population. The introduction of Introduction molecular inhibitors of vascular endothelial growth factor (VEGF), such as pegaptanib, The introduction of inhibitors of vascular ranibizumab, and bevacizumab, as treatments endothelial growth factor (VEGF)-A to the for exudative AMD has provided new hope for world of ophthalmology has transformed the affected patients and has transformed the management of age-related macular practices of retina specialists. Phase III degeneration (AMD), the leading cause of clinical trials have demonstrated the efficacy blindness among the ageing population in the and safety of monthly ranibizumab for the developing world.1 Retina specialists have preservation as well as improvement of visual largely embraced this new class of medication, acuity in patients with exudative AMD. which has for the first time offered the hope of Ongoing trials are evaluating the effectiveness visual improvement to patients suffering from of different dosing regimens, monitoring AMD. Although a large body of data supports strategies, and combination therapies to the efficacy of intravitreal
    [Show full text]